Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020
NEW YORK, Oct. 18, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020
http://www.reportlinker.com/p0657236/Gardasil-Cervical-Cancer---Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020
Summary
GlobalData's pharmaceuticals report, "Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020" provides Gardasil sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes information on Cervical Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.
Scope
- Therapy area profile including patient population for the US and EU5
- Analysis and review of Gardasil including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Gardasil including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts for 2006-2020 for Gardasil in the US and EU5
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Cervical Cancer Vaccines Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 HPV Infections 6
2.3.2 Lack of Regular Papanicolaou (pap) Tests 7
2.3.3 Smoking 7
2.3.4 Sexual History 8
2.3.5 Birth Control Pills 8
2.4 GlobalData Report Guidance 8
3 Cervical Cancer Vaccines: Market Characterization 9
3.1 Cervical Cancer Vaccines Market 9
3.2 Drivers and Challenges for the Cervical Cancer Market 9
3.2.1 Drivers for Cervical Cancer Vaccine Market 9
3.2.2 Challenges for Cervical Cancer Vaccines 10
4 Gardasil (human papillomavirus vaccine(types6,11,16,18)) 11
4.1 Introduction 11
4.2 Human Papillomavirus Vaccine (HPV) 11
4.3 Mechanism of Action 11
4.4 Clinical Studies of Gardasil 11
4.4.1 Phase I and II trial 11
4.4.2 Phase III trial 12
4.5 Factors Affecting Sales 12
4.5.1 Cervical Cancer Market 12
4.5.2 Better Efficacy 13
4.5.3 Wide Disease Coverage 13
4.5.4 Public Health Advantage 13
4.5.5 Cost Effectiveness 13
4.5.6 Barriers to the Vaccination 13
4.6 Vaccine Evaluation 14
4.6.1 Efficacy 14
4.6.2 Safety 14
4.6.3 Dosing Convenience 15
4.6.4 Intensity of Competition 15
4.7 Sales forecast 16
4.7.1 Eligible population for Gardasil 16
4.7.2 Dosing 16
4.7.3 Market Penetration 16
4.7.4 Annual Cost of Therapy 17
4.7.5 Sales Projections of Gardasil 17
5 Cervical Cancer Vaccine Market: Appendix 24
5.1 Market Definitions 24
5.2 List of Abberiviations 24
5.3 Research Methodology 24
5.3.1 Coverage 25
5.3.2 Secondary Research 25
5.3.3 Forecasting 25
5.3.4 Population Approved to take Vaccine 26
5.3.5 Net Penetration of Vaccine 26
5.3.6 Net Annual Dosing 27
5.3.7 Annual Cost of Therapy 27
5.3.8 Primary Research 27
5.3.9 Expert Panels 27
5.4 Contact Us 27
5.5 Disclaimer 28
1.1 List of Tables
Table 1:Cervical Cancer, Estimated Incidences and Mortality, 2010-2020 5
Table 2: Estimated Prevalence of HPV in 9-26 years women 7
Table 3: Gardasil, Cervical Cancer Global, Sales Forecast ($m), 2006–2020 17
Table 4: Gardasil, Cervical Cancer, the US, Sales Forecast ($m), 2006–2020 18
Table 5: Gardasil, Cervical Cancer, UK, Sales Forecast ($m), 2006–2020 19
Table 6: Gardasil, Cervical Cancer, France, Sales Forecast ($m), 2006–2020 20
Table 7: Gardasil, Cervical Cancer, Germany, Sales Forecast ($m), 2006–2020 21
Table 8: Gardasil, Cervical Cancer, Italy, Sales Forecast ($m), 2006–2020 22
Table 9: Gardasil, Cervical Cancer, Spain, Sales Forecast ($m), 2006–2020 23
1.2 List of Figures
Figure 1: Estimated Prevalence of HPV in Women Aged between 9-26 Years in the US,EU-5 and Japan, 2010-2020 1
Figure 2: Distribution of Incidence and Mortality, Global, Top 26 Diagnosed Cancers,2010 4
Figure 3: Difference Between Percentage Distribution of Incidence and Mortality of Top 19 Cancers, 2008 6
Figure 4: Per Capita Cigarette Consumption, the US, 1976-2006 7
Figure 5: Efficacy comparison : Gardasil and Cervarix 14
Figure 6: Eligible population for Gardasil 16
Figure 7: Gardasil, Cervical Cancer Global, Sales Forecast ($m), 2006–2020 17
Figure 8: Gardasil, Cervical Cancer, the US, Sales Forecast ($m), 2006–2020 18
Figure 9: Gardasil, Cervical Cancer, UK, Sales Forecast ($m), 2006–2020 19
Figure 10: Gardasil, Cervical Cancer, France, Sales Forecast ($m), 2006–2020 20
Figure 11: Gardasil, Cervical Cancer, Germany, Sales Forecast ($m), 2006–2020 21
Figure 12: Gardasil, Cervical Cancer, Italy, Sales Forecast ($m), 2006–2020 22
Figure 13: Gardasil, Cervical Cancer, Spain, Sales Forecast ($m), 2006–2020 23
Figure 14: GlobalData Methodology 24
To order this report:
Pathology Industry: Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020
Pathology Business News
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article